Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.49 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.34 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rdv-Tp SCHEMBL26003192 | 0.92 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL24492746 | 0.92 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL10120881 | 0.92 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL24492745 | 0.92 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL23278555 | 0.92 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| SCHEMBL17719238 | 0.90 | POLRMT (0.48) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| SCHEMBL15998264 | 0.86 | TMPRSS2 (0.46) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| SCHEMBL26753688 | 0.86 | TMPRSS2 (0.48) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| SCHEMBL26753667 | 0.86 | TMPRSS2 (0.46) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| SCHEMBL881568 | 0.85 | POLRMT (0.49) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287029-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287029-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | MTAP, SARS1, RNGTT | POLRMT 20/4885TMPRSS2 181/4885P2RX1 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.